# GLP-1- en dual-receptoragonisten: nieuwe consensus over toepassing bij type 2-diabetes

*geplaatst 2026-09-01 · Hartfalen · Zhonghua yi xue za zhi · doi 10.3760/cma.j.cn112137-20260527-01398 · https://hartvaat.nl/2026/08/25/glp-1-en-dual-receptoragonisten-nieuwe-consensus-over-toepassing-bij-type-2-diab/*

Een Chinese expertconsensus uit 2026 geeft richtlijnen voor het gebruik van GLP-1-receptoragonisten (GLP-1-, GIP/GLP-1- en GCG/GLP-1-agonisten) bij patiënten met type 2-diabetes. De 10 aanbevelingen focussen op de juiste indicatie, combinatiemogelijkheden met andere glucoseverlagende middelen, en de cardiovasculaire, renale en hepatologische voordelen van deze stoffen. Voor de klinische praktijk biedt de update een gestructureerd kader om deze groeiende medicijngroep veiliger en effectiever in te zetten in de diabeteszorg.

## English: [Expert consensus on the clinical application of nutrient-stimulated hormone receptor agonist in the treatment of type 2 diabetes mellitus (2026 edition)].

A 2026 expert consensus provides updated recommendations for the clinical use of glucagon-like peptide-1 (GLP-1) receptor agonists, including GLP-1, GIP/GLP-1, and GCG/GLP-1 receptor agonists, in type 2 diabetes. The guidance outlines optimal patient selection, combination strategies with other antidiabetic agents, and highlights the established cardiovascular, renal, and hepatic benefits of these agents. For clinicians, the consensus offers a practical framework to standardize prescribing and optimize cardiometabolic outcomes in diabetes management.

## Abstract (original, from the publication)

Hypoglycemic drugs targeting at nutrient-stimulated hormone (NuSH) receptors, including glucagon like peptide-1 (GLP-1) receptor agonists, dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists and dual glucagon (GCG)/GLP-1 receptor agonists, not only exhibit the beneficial metabolic effects, such as lowering blood glucose, reducing body weight, lowering blood pressure, improving lipid profiles and attenuating hepatic steatosis, but also have demonstrated cardiovascular and renal benefits. The continual innovation and advancement of novel drugs, along with the continuous accumulation of evidence-based medical evidence, have offered more options for the clinical management of type 2 diabetes mellitus (T2DM). Based on these developments, Endocrinology and Metabolism Professional Committee, National Association of Health Industry and Enterprise Management searched recent literature and evaluated its evidence, and organized endocrinology specialists to conduct multiple rounds of rigorous deliberation and repeated revisions to complete the update of the consensus, on the basis of the 2020 version of the Consensus recommendations on utilizing glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus.The consensus focuses on the timing and applicable population of NuSH receptor agonists in T2DM, the precautions when combined with other hypoglycemic drugs, the impacts on cardiovascular, renal or hepatic outcomes, forming 10 recommended opinions aimed at providing reference for clinical doctors to standardize the use of such drugs and better serve T2DM patients.

---
Bron: Zhonghua yi xue za zhi, https://doi.org/10.3760/cma.j.cn112137-20260527-01398. Bijgewerkt 2026-08-25T01:18:19Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.